Everything below concerns GW501516. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
The National Safety Council calculated that the lifetime odds of dying from an opioid overdose (1 in 96) in 2017 were greater than the lifetime odds of dying in an automobile accident (1 in 103) in the United States. The opioid epidemic, combined with the Patient Protection and Affordable Care Act, has led to a situation called the Florida shuffle, where a drug user moves between drug rehabilitation centers so those centers may bill the user's insurance company. In one study, a decision analytical model of the US population aged 12 years or older found that "under the status quo, an estimated 484,429 individuals were projected to die of fatal opioid overdose" between 2020 and 2029. However, a combination of "reducing opioid prescribing, increasing naloxone distribution, and expanding treatment for opioid use disorder was associated with an estimated 179,151 lives saved when compared to the status quo." Healthcare professionals are also among those heavily affected by this epidemic. Studies have been done to determine how well nursing students, nurses, and even doctors are prepared to treat patients affected by opioid addictions. The studies have pointed to the fact that nurses and other healthcare professionals are highly undertrained in this area. As a result, many specific education programs have been proposed and implemented into nursing education institutions.
== Academic and professional activities == Throughout 37 years of activity, Mendes published some 150 articles, During this time, he created various inventions and innovations in the field of Implant Surgery, Bio materials, Orthopedic instruments and surgical techniques. As a result, he is the owner of several international patents. Mendes introduced the Total Knee Arthroplasty operation for the first time in Israel, a technology he studied in the USA. By combining materials developed in Germany and France, he was able to extend the service life of the implant. As part of his activities in the Center for Implant Surgery, Mendes created a platform for cooperation with researchers from the Technion, the Hebrew University and the high tech industry. These efforts were directed at the investigation of influence of different types of energy on bone restructure and fracture healing, development of new implants and replacement parts for joints and ligaments and contributed to the arising field of Computed Tomography. Together with International teams financed by the German-Israel Foundation, Mendes managed several research efforts into the replacement of ligaments with synthetic fibers and the design of artificial replacement of the bony patella.
Yaws is a tropical infection of the skin, bones, and joints caused by the spirochete bacterium Treponema pallidum pertenue. The disease begins with a round, hard swelling of the skin, 2 to 5 cm (0.79 to 1.97 in) in diameter. The center may break open and form an ulcer. This initial skin lesion typically heals after 3–6 months. After weeks to years, joints and bones may become painful, fatigue may develop, and new skin lesions may appear. The skin of the palms of the hands and the soles of the feet may become thick and break open. The bones (especially those of the nose) may become misshapen. After 5 years or more, large areas of skin may die, leaving scars. Yaws is spread by direct contact with the fluid from a lesion of an infected person. The contact is usually nonsexual. The disease is most common among children, who spread it by playing together. Other related treponemal diseases are bejel (T. pallidum endemicum), pinta (T. carateum), and syphilis (T. p. pallidum). The appearance of the lesions often diagnoses yaws. Blood antibody tests may be useful, but cannot separate previous from current infections. Polymerase chain reaction is the most accurate method of diagnosis. No vaccine has yet been found. Prevention is, in part, done by curing those who have the disease, thereby decreasing the risk of transmission. Where the disease is common, treating the entire community is effective. Improving cleanliness and sanitation also decreases the spread. Treatment is typically with antibiotics, including azithromycin by mouth or benzathine penicillin by injection.
Sources: en.wikipedia.org
==== Aerosol mass spectrometer ==== The Aerodyne AMS provides real-time aerosol mass spectrometry analysis of size-resolved mass concentration of non-refractory components (Ex. organics, sulfate, nitrate, and ammonium). The term non-refractory is assigned to species that evaporate rapidly at 600 °C under vacuum conditions (e.g. organic matter, NH4NO3 and (NH4)2SO4. The schematic of a typical AMS is shown in the figure to the right. The Aerodyne AMS is made up of three sections; The aerosol inlet, the particle sizing chamber, and the particle detection chamber. The aerosol inlet has a flow limiting orifice entrance that is around 100 um in diameter. Once in the chamber the sample goes through aerodynamic focusing lens system, which consist of several orifice lenses that are mount in sequence of decreasing inner diameter. The lens focuses the particles into a narrow particle beam. The beam now travels through the particle sizing chamber, where the particle aerodynamic diameter is measured. The particle sizing chamber is made up of a flight tube maintained at (~ 10−5 torr). The entrance of the flight tube is a mechanical chopper that's used to modulate the particle beam; then using both the fixed length of the tube and the time-resolved detection of the arrival at the end, the particles' velocities can be determined. Using the velocity, the particle's diameter is obtained. As the particle beam exits the flight tube, it enters the particle composition detection chamber. In this section, the particles collide with a heated tungsten element (~600 °C).
== Uses == The drug Prajmaline has been used to treat a number of cardiac disorders. These include: coronary artery disease, angina, paroxysmal tachycardia and Wolff–Parkinson–White syndrome. Prajmaline has been indicated in the treatment of certain disorders where other antiarrhythmic drugs were not effective.
Gerald A. LeBlanc is an American biologist, toxicologist, author, and academic. He is a Professor Emeritus in the Department of Biological Sciences at the North Carolina State University. LeBlanc's research interests span the fields of environmental toxicology and risk assessment with a focus on investigating the processes involved in the endocrine regulation of reproduction and development, as well as how environmental agents can disrupt these processes. He is the author of the book, Everyday Chemicals: Understanding the Risks and has published over 190 articles.
Dental plaque is a microbial biofilm which forms on teeth. This biofilm may calcify and harden, termed calculus (tartar). Plaque tends to build up around the gingival margin (the gumline) and in gingival crevices or periodontal pocket (below the gumline). The release of waste products from the bacteria living in the biofilm causes an inflammatory response in the gums which become red and swollen, bleeding easily when disturbed. This is termed plaque-induced gingivitis and represents the most common form of gingival disease. This inflammatory response in the host can be strongly influenced by many factors such as hormonal fluctuations, drugs, systemic diseases, and malnutrition; which may allow further subdivision of plaque-induced gingivitis (see table).
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.